Abstract-In the rostral ventrolateral medulla (RVLM), angiotensin II-derived superoxide anions, which increase sympathetic nerve activity, induce a pressor response by activating the p38 mitogen-activated protein kinase (p38 MAPK) and extracellular signal-regulated kinase (ERK) pathway. The small G protein Ras mediates a caspase-3-dependent apoptotic pathway through p38 MAPK, ERK, and c-Jun N-terminal kinase. We hypothesized that angiotensin II type 1 receptors activate caspase-3 through the Ras/p38 MAPK/ERK/c-Jun N-terminal kinase pathway in the RVLM and that this pathway is involved in sympathoexcitation in stroke-prone spontaneously hypertensive rats (SHRSP), a model of human hypertension. The activities of Ras, p38 MAPK, ERK, and caspase-3 in the RVLM were significantly higher in SHRSP (14 to 16 weeks old) than in age-matched Wistar-Kyoto rats (WKY). The mitochondrial apoptotic proteins Bax and Bad in the RVLM were significantly increased in SHRSP compared with WKY. c-Jun N-terminal kinase activity did not differ between SHRSP and WKY. In SHRSP, intracerebroventricular infusion of a Ras inhibitor significantly reduced sympathetic nerve activity and improved baroreflex sensitivity, partially because of inhibition of the Ras/p38 MAPK/ERK, Bax, Bad, and caspase-3 pathway in the RVLM. Intracerebroventricular infusion of a caspase-3 inhibitor also inhibited sympathetic nerve activity and improved baroreflex sensitivity in SHRSP. Intracerebroventricular infusion of an angiotensin II type 1 receptor blocker in SHRSP partially inhibited the Ras/p38 MAPK/ERK, Bax, Bad, and caspase-3 pathway in the RVLM. These findings suggest that in SHRSP, angiotensin II type 1 receptor-activated caspase-3 acting through the Ras/p38 MAPK/ERK pathway in the RVLM might be involved in sympathoexcitation, which in turn plays a crucial role in the pathogenesis of hypertension. (Hypertension. 2010;55:291-297.)
euronal apoptosis in the brain is involved in regulating synaptic plasticity and neural function [1] [2] [3] and is mainly caused by reactive oxygen species (ROS). 4 -8 Ras is a member of a superfamily of related small GTPases implicated in cellular proliferation and transformation, growth arrest, senescence, and apoptosis. 9 -13 In cultured tumor cells or endothelial cells, the proapoptotic effects of Ras are mediated by the p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) pathway through phosphorylation of the proapoptotic proteins Bax and Bad and the antiapoptotic protein Bcl-2, which releases cytochrome c in the mitochondria. 14 -17 Neuronal apoptosis is characterized by the release of cytochrome c, which activates caspase-3, the major executioner caspase in neurons. 18, 19 Thus, neuronal apoptosis may be mainly mediated by caspase-3 through the Ras, p38 MAPK, ERK pathway. We previously demonstrated that ROS in a cardiovascular center of the brain stem increase sympathetic nerve activity (SNA) in hypertensive rats. 20 Accumulating evidence suggests that ROS in the brain are involved in the neural mechanisms of hypertension. 21, 22 Although ROS are increased in the brain in a hypertensive state, it is not known whether a pivotal signaling pathway (such as the Ras, p38 MAPK, ERK pathway) and caspase-3, activated by ROS in the brain, are chronically activated in the hypertensive state or whether this pathway activates SNA.
The rostral ventrolateral medulla (RVLM) in the brain stem is a major vasomotor center, and it regulates SNA. 23, 24 We previously demonstrated that ROS in the RVLM activates SNA and that ROS are increased in the RVLM of strokeprone spontaneously hypertensive rats (SHRSP), a model of human hypertension, 25 with activation of SNA. 20 In the brain, ROS are produced by activation of the angiotensin II type 1 receptor (AT 1 R), which in turn activates nicotinamide-adenine dinucleotide phosphate (NAD[P]H) oxidase. 26 NAD(P)H oxidase-derived superoxide anions mediate the angiotensin II-induced pressor effect via the activation of p38 MAPK and ERK in the RVLM. 27 Furthermore, in experimental endotoxemia, the proapoptotic protein Bax and caspase-3-dependent apoptosis in the RVLM mediate cardiovascular responses. 28 The mechanisms by which ROS in the RVLM regulate SNA have not been fully examined, especially the pivotal signaling pathway of ROS.
The aims of the present study were to determine whether stimulation of endogenous AT 1 R activates caspase-3 through the Ras/p38 MAPK/ERK/c-Jun N-terminal kinase (JNK) pathway in the RVLM and, if so, to determine whether activation of this pathway is involved in the increased sympathoexcitation in SHRSP. Toward this end, we examined the activity of Ras, p38 MAPK, ERK, JNK, proapoptotic proteins Bax and Bad, antiapoptotic protein Bcl-2, and caspase-3 in the RVLM of SHRSP and normotensive rats. In addition, we performed intracerebroventricular (ICV) injections of a Ras inhibitor, a caspase-3 inhibitor, and an angiotensin receptor blocker (ARB), and examined the changes in blood pressure, heart rate (HR), SNA, and baroreflex sensitivity (BRS). To determine whether ICV injection of a Ras inhibitor, a caspase-3 inhibitor, or an ARB inhibits the pivotal signaling pathway in the RVLM, we also examined the changes in blood pressure, HR, and SNA evoked by microinjection of angiotensin II into the RVLM.
Methods
This study was reviewed and approved by the Committee on the Ethics of Animal Experiments at the Kyushu University Graduate School of Medical Sciences and conducted according to the Guidelines for Animal Experiments of Kyushu University. Details of the methods are available in the online Data Supplement at http://hyper.ahajournals.org.
Animals and General Procedures
Male SHRSP/Izm rats and age-matched Wistar-Kyoto rats (WKY) ( ; nϭ5/group). In the S-RI, W-RI, S-CI, W-CI, S-Veh, W-Veh, and S-ARB groups, we measured blood pressure and HR using a radiotelemetry system as described previously. 20 Urinary norepinephrine excretion (uNE) for 24 hours was calculated as an indicator of SNA, as described previously. 20, 22 Furthermore, in the S-RI, W-RI, S-CI, W-CI, S-Veh, and W-Veh groups, spectral analysis was performed to provide power spectra for systolic blood pressure. We also determined the changes in blood pressure and HR of SHRSP after terminating the 14-day ICV infusion of the Ras inhibitor (nϭ4). The candesartan dose was selected as described previously. 32 
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Statistical Analysis
Normally distributed variables are expressed as meanϮSE. Unpaired t and Mann-Whitney U tests were used to compare the differences in normally distributed and nonnormally distributed variables, respectively. Data were also analyzed by a 2-factor repeated-measures analysis of variances. Differences were considered to be statistically significant at PϽ0.05.
Results
Blood Pressure, HR, SNA, and BRS
The Ras inhibitor S-farnesylthiosalicylic acid was infused ICV for 14 days. Mean blood pressure (MBP), HR, uNE, and normalized unit of the low-frequency component of systolic blood pressure (LFnuSBP) at day 14 were significantly higher in S-Veh than in W-Veh ( Figure 1A through 1D) . MBP, HR, and LFnuSBP in SHRSP returned to control levels 4 days after terminating the ICV infusion of S-farnesylthiosalicylic acid (data not shown). BRS at day 14 was significantly lower in S-Veh than in W-Veh (Figure 2 ). At days 2 to 14, MBP and HR were significantly lower in S-RI than in S-Veh ( Figure 1A and 1B), and at day 14, uNE and LFnuSBP were significantly lower in S-RI than in S-Veh ( Figure 1C and 1D ). BRS at day 14 was significantly higher in S-RI than in S-Veh (Figure 2) . MBP, HR, LFnuSBP, uNE, and BRS, however, did not differ between W-RI and W-Veh (Figures 1A through 1D and 2).
The caspase-3 inhibitor Z-DEVD-FMK was infused ICV for 14 days. At days 4 to 14, MBP and HR were significantly lower in S-CI than in S-Veh ( Figure 1A and 1B), and at day 14, uNE and LFnuSBP were also significantly lower in S-CI than in S-Veh ( Figure 1C and 1D ). BRS at day 14 was significantly higher in S-CI than in S-Veh ( Figure 2 ). MBP, HR, LFnuSBP, uNE, and BRS did not differ between W-CI and W-Veh (Figures 1A through 1D and 2).
On day 14 of the ICV infusion of candesartan in SHRSP, the systolic blood pressure, HR, uNE, and LFnuSBP were significantly lower in S-ARB than in S-Veh (Figures 1A through 1D). The expression of Bcl-2 was significantly lower in S-Veh than in W-Veh ( Figure 4D ) and significantly higher in S-RI than in S-Veh ( Figure 4D ). In WKY, however, the expression of Bcl-2 did not differ between W-Veh and W-RI ( Figure 4D ). ICV infusion of candesartan in SHRSP significantly increased Bcl-2 expression ( Figure 4D ).
S-RI than in S-
Microinjection of Angiotensin II into the RVLM
The changes in MBP, HR, and LFnuSBP evoked by microinjection of angiotensin II into the bilateral RVLM were significantly smaller in S-RI than in S-Veh (MBP, 8Ϯ5 mm Hg versus 14Ϯ3 mm Hg; HR, 7Ϯ8 bpm versus 22Ϯ9 bpm; LFnuSBP, 3Ϯ3% versus 8Ϯ2%; nϭ5 for each; PϽ0.01).
Discussion
The novel findings in the present study are as follows: (1) Ras, p38 MAPK, ERK, mitochondrial apoptotic proteins Bax and Bad, and caspase-3 in the RVLM are activated in SHRSP; (2) ICV infusion of a Ras inhibitor decreases MBP, HR, and SNA and increases BRS through the partial inhibition of p38 MAPK, ERK, Bax, Bad, and caspase-3 in the RVLM of SHRSP; (3) ICV infusion of a caspase-3 inhibitor decreases MBP, HR, and SNA and increases BRS through the partial inhibition of caspase-3 in the RVLM of SHRSP; (4) ICV infusion of candesartan decreases systolic blood pressure, HR, and SNA through the partial inhibition of Ras, p38 MAPK, ERK, Bax, Bad, and caspase-3 in the RVLM of SHRSP; and (5) ICV infusion of the Ras inhibitor in SHRSP abolishes the pressor effect evoked by the microinjection of angiotensin II into the RVLM. These findings indicate that AT 1 R-induced activation of caspase-3 through the Ras/p38 MAPK/ERK pathway in the RVLM might increase MBP, HR, and SNA and decrease BRS ( Figure 5 ).
The present findings are the first to demonstrate that Ras, p38 MAPK, and ERK activity is increased in the RVLM of SHRSP. A previous study suggested that an acute injection of angiotensin II induced AT 1 R-dependent ROS production and phosphorylation of p38 MAPK and ERK in the RVLM. 27 Activation of p38 MAPK and ERK by angiotensin II is also reported in mesenteric smooth muscle cells 33, 34 and aorta. 35, 36 In the forebrain, MAPK is activated in a model of heart failure in which the brain renin-angiotensin system is upregulated. 37 ROS activates Ras, 38 and Ras activates caspase-3 through p38 MAPK and ERK. 4 -7,39 Previously, we demon- strated that ROS in the RVLM increases SNA, 20, 22 and ROS is produced in the brain by angiotensin II and NAD(P)H oxidase. 25 In the present study, ICV infusion of the Ras inhibitor decreased MBP, HR, and SNA and increased BRS because of the partial inhibition of Ras, p38 MAPK, ERK, and caspase-3 in the RVLM of SHRSP, and it abolished the pressor effect evoked by the microinjection of angiotensin II into the RVLM. ICV infusion of the caspase-3 inhibitor also inhibited MBP, HR, and SNA and increased BRS through the partial inhibition of caspase-3 activity in the RVLM of SHRSP. Furthermore, ICV infusion of candesartan decreased MBP, HR, and SNA, consistent with previous reports. 32 In the present study, ICV infusion of candesartan also partially inhibited Ras, p38 MAPK, ERK, and caspase-3 in the RVLM of SHRSP. The degree of the depressor effect of the Ras inhibitor on MBP in SHRSP was almost half that in WKY. These results suggest that AT 1 R-activated caspase-3 acting through the Ras/MAPK/ERK pathway in the RVLM is one of the major pathways through which MBP, HR, and SNA are increased and BRS is decreased in SHRSP.
Another intriguing finding of the present study is that the apoptotic proteins Bax and Bad were activated, and the antiapoptotic protein Bcl-2 was inhibited in the RVLM of SHRSP. Neuronal apoptosis is mediated by caspase-3 activated by Bax and Bad and inhibited by Bcl-2 in mitochondria. 1 Activation of caspase-3 induces neuronal apoptosis. 18, 19 Other reports indicate that p38 MAPK and ERK activate caspase-3-dependent neuronal apoptosis. 8 We previously demonstrated that mitochondria-derived ROS mediate sympathoexcitation induced by angiotensin II in the RVLM, 40 and these results suggest that mitochondrial dysfunction in the RVLM causes sympathoexcitation via ROS production. We hypothesized that Ras, p38 MAPK, and ERK activate the mitochondrial apoptotic pathway and inhibit the mitochondrial antiapoptotic pathway and that caspase-3-dependent neuronal apoptosis is activated in the RVLM of SHRSP. The possibility of caspase-3-independent neuronal apoptosis in the RVLM or of a direct link between ROS and caspase-3 activation was not examined in the present study. A previous report suggested that neural apoptosis in the RVLM leads to a reduction of sympathetic outflow. 40 Further study is necessary to determine the reasons for this discrepancy.
In the present study, we determined the ICV infusion dose of the Ras or caspase-3 inhibitor that inhibits blood pressure, HR, and SNA. There were dose-dependent effects of the Ras and caspase-3 inhibitors on blood pressure and HR (data not shown). Furthermore, the doses of Ras or caspase-3 inhibitor used in the present study did not change blood pressure or HR when injected intravenously (data not shown). In addition, Ras and caspase-3 activity were significantly higher in SHRSP than in WKY, and the depressor and sympathoinhibitory effects of Ras and caspase-3 inhibitors were also significantly greater in SHRSP than in WKY. Thus, we consider that the doses of Ras and caspase-3 inhibitor used in the present study were reasonable to inhibit Ras or caspase-3 activity in the RVLM. Future studies, however, are needed to investigate the effects of inhibiting Ras or caspase-3 activity specifically in the RVLM.
Interestingly, JNK was not altered in the RVLM of SHRSP. JNK is an upstream activator of apoptosis. In a heart failure model, JNK is upregulated in the RVLM. 41 Angiotensin II and NAD(P)H oxidase-derived superoxide anions, however, do not activate JNK in the RVLM, 27 and these findings are consistent with the present results. We did not explore the mechanisms of this discrepancy in the present study and are therefore not able to exclude the importance of JNK in the RVLM for cardiovascular regulation. JNK in the RVLM might be significantly activated in heart failure progressing to hypertension. Furthermore, we did not examine the protein kinase C-dependent pathway in the RVLM. A previous report indicates that protein kinase C-dependent translocation of Bax in the RVLM initiates caspase-3-dependent apoptosis during experimental endotoxemia. 28 It is possible that this pathway is also a major pathway involved in the increase in SNA in SHRSP.
The present study has some limitations. Ras activity in the RVLM was inhibited by ICV infusion of the Ras inhibitor, and the inhibition of Ras activity was not limited to the RVLM; therefore, we cannot exclude the possible effects of Ras inhibition in other brain sites, and our results do not suggest that the AT 1 R/Ras/caspase-3 pathway in the RVLM is the only major pathway of the sympathetic control. Moreover, none of the ICV antagonists completely normalized BP, HR, and SNA in SHRSP. Many factors in the RVLM may be involved in changing SNA. Nevertheless, Ras activity was inhibited in the RVLM, and, therefore, the neural activity of the RVLM directly influenced SNA. 23, 24 Furthermore, we found that the pressor effect evoked by microinjection of angiotensin II into the RVLM was attenuated in SHRSP treated with ICV infusion of the Ras inhibitor. Previous reports suggest that activation of the brain angiotensin system contributes to the neural mechanisms of hypertension. 23, 24, [42] [43] [44] [45] In addition, a renin-angiotensin system also exists inside the blood-brain barrier. 42, 46 All components of the renin-angiotensin system are present in the brain, such as renin, angiotensinogen, angiotensin-converting enzyme, angiotensin II, and AT 1 and angiotensin type 2 (AT 2 ) receptors. 45 Importantly, AT 1 receptors are richly distributed in the paraventricular nucleus of the hypothalamus, nucleus tractus solitarius, and RVLM, which are involved in autonomic cardiovascular regulation. 42,44 -46 Therefore, it is conceivable that alteration of a signaling pathway in the RVLM influences central sympathetic outflow via AT 1 R in the RVLM of SHRSP, although we cannot exclude the possible interaction of other autonomic nuclei, such as the paraventricular nucleus of the hypothalamus. The findings of the present study do not exclude the possibility that similar effects might occur in other nuclei or that these findings are indirect effects. In this regard, further study is necessary to determine the role of other autonomic nuclei in neural control of blood pressure. It would be interesting if we could examine the direct effect of chronic infusion of a Ras inhibitor and/or a caspase inhibitor directly into the RVLM. In addition, we did not measure SNA directly in the present study because chronic direct measurement of SNA is technically difficult. We examined SNA by measuring 24-hour uNE and spectral analysis of systolic blood pressure. uNE is considered to be a measure of SNA, 20, 47 and measurement of uNE is often used to assess SNA in small awake animals. 47 We consider that uNE and LFnuSBP are appropriate parameters for assessing SNA.
In conclusion, AT 1 R-induced activation of caspase-3 through Ras/p38 MAPK/ERK and the mitochondrial apoptotic pathway in the RVLM of SHRSP increases blood pressure, HR, and SNA 
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and decreases BRS in SHRSP. Inhibition of this pathway by ARB in the RVLM may be a novel therapeutic approach to sympathoexcitation in hypertension.
Perspectives
Our results suggest that Ras-activated caspase-3, acting through the p38 MAPK, ERK, and mitochondrial apoptotic pathways in the RVLM, increases SNA. Previous studies indicate that angiotensin II and ROS produced by NAD(P)H oxidase are upstream of Ras. In the RVLM, angiotensin II and ROS are important modulating factors regulating SNA, which is involved in cardiovascular disease, such as hypertension and heart failure. We consider that neural apoptosis in the RVLM is a novel target for the treatment of cardiovascular diseases exhibiting increased SNA.
Supplemental Methods
This study was reviewed and approved by the Committee on the Ethics of Animal Experiments at the Kyushu University Graduate School of Medical Sciences and conducted according to the Guidelines for Animal Experiments of Kyushu University.
Animals and General Procedures
Male SHRSP/Izm rats and age-matched Wistar-Kyoto (WKY) rats (14-16 weeks-old; SLC Japan, Hamamatsu, Japan), fed standard feed, were divided into seven groups (SHRSP treated with Ras inhibitor, S-RI; SHRSP treated with caspase-3 inhibitor, S-CI; SHRSP treated with an angiotensin receptor blocker [ARB], S-ARB; SHRSP treated with vehicle, S-Veh; WKY treated with Ras inhibitor, W-RI; WKY treated with caspase-3 inhibitor, W-CI; and WKY with vehicle, W-Veh; n=5 for each). In the S-RI, W-RI, S-CI, W-CI, S-Veh, W-Veh, and S-ARB groups, we measured blood pressure, and heart rate (HR) using the UA-10 radiotelemetry system (Data Science International) as described previously. 1 Urinary norepinephrine concentrations were measured, and urinary norepinephrine excretion (uNE) for 24 hours was calculated as an indicator of sympathetic nerve activity (SNA), as described previously.
1, 2 Furthermore, in the S-RI, W-RI, S-CI, W-CI, S-Veh, and W-Veh groups, spectral analysis was performed using an adaptive auto-regressive model to provide power spectra for systolic blood pressure (SBP). Blood pressure was recorded for 5 minutes between 9AM and 12 PM every day, and we then determined the total power of SBP and the total spectral density of the variables. The relative value of each spectral power component was also measured and expressed in normalized units. The low frequency (LF) power of SBP was computed by integrating the spectra between 0.04 and 0.15 Hz, and SNA was calculated using the normalized unit of the LF component of SBP (LFnuSBP). [3] [4] [5] [6] Baroreflex sensitivity (BRS) was measured using a spontaneous sequence method as a parameter of autonomic control. Sequence analysis detected sequences of three or more beats in which there was either an increase in SBP and pulse interval (PI; Up-Sequence) or a decrease in SBP and PI (Down-Sequence). BRS was estimated as the mean slope of the Up-and Down-Sequences. 7, 8 To obtain the RVLM tissues, the rats were deeply anesthetized with sodium pentobarbital (100 mg/kg IP) and perfused transcardially with phosphate-buffered saline (PBS; 150 mol/L NaCl, 3 mmol/L KCl, and 5 nmol/L phosphate; pH 7.4, 4°C). The brains were removed quickly, and 1-mm thick sections were cut using a cryostat at -7±1°C. The RVLM was defined according to a rat brain atlas, as described previously.
1
Activity of Ras, p38 MAPK, ERK, and JNK in the RVLM The Ras activity was determined by measuring the expression of Ras-GTP per total Ras. 9 The activities of p38 MAPK, ERK, and JNK were determined by measuring the expression of the phosphorylated form of each protein per total Ras, p38 MAPK, ERK, and JNK, respectively. The expression of phosphorylated or total RAS, p38 MAPK, ERK, and JNK in the RVLM tissue was determined by Western blot analysis.
Activity of Caspase-3 and Expression of Bax, Bad, and Bcl-2 in the RVLM The caspase-3 activity in the cytosolic fraction of the RVLM tissues was measured using the synthetic substrate acetyl-Asp-Glu-Val-Asp-7-amido-4 methyl coumarin (Ac-DEVD-AMC), as described previously. 10 The reactions were incubated at 37°C and the release of the fluorescent product was monitored with a spectrofluorometer using excitation and emission wavelengths of 380 and 440 nm, respectively. The expression of Bax, Bad, and Bcl-2 in the mitochondrial fraction of RVLM tissues was determined by Western blot analysis. 12 FTS, Z-DEVD-FMK, candesartan (1 μg/μl), or DMSO in aCSF as vehicle was infused at 0.5 μl/h for 14 days with an osmotic minipump (Alzet 1003D; Alza Scientific Products), the cannula of which was placed in the left ventricle (from bregma: anteroposterior, −0.8 mm; lateral, 1.5 mm; depth, 3.5 mm) of SHRSP and WKY. These doses of FTS and Z-DEVD-FMK were determined to decrease blood pressure, HR, and SNA in SHRSP. Changes in blood pressure and HR were measured in SHRSP after terminating the 14-day ICV infusion of the Ras inhibitor (n=4). The dose of candesartan used has no centrally mediated antihypertensive effect in SHR and SHRSP and blocks changes in blood pressure and HR in response to ICV infusion of angiotensin II.
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13
Microinjection of Angiotensin II into the RVLM
Telemetry was used to monitor the changes in mean blood pressure (MBP), HR, and LFnuSBP evoked by the bilateral microinjection of angiotensin II (25 pmol in 50 nL of PBS) into the RVLM of S-RI or S-VEH in anesthetized rats 14 days after beginning the ICV infusion. The microinjection procedures and the method used to verify cannula placement in the RVLM were described previously. 
Statistical Analysis
Normally distributed variables are expressed as mean ± SE. Unpaired t and Mann-Whitney U tests were used to compare the differences in normally distributed and non-normally distributed variables, respectively. Data were also analyzed by a two-factor repeated-measures analysis of variance. Differences were considered to be statistically significant at a P value of less than 0.05.
